Trial Profile

An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olesoxime (Primary) ; Riluzole
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Sponsors Roche; Trophos

Most Recent Events

22 Jun 2013 Planned number of patients changed from 271 to 350 as reported by United Kingdom Clinical Research Network.
22 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network: 10407).
09 Apr 2013 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com